Phase II clinical trial of immunotherapy with WT1 peptide vaccination for pediatric hematological malignancies after allogeneic stem cell transplantation.
Not Applicable
- Conditions
- Acute lymphoid or myeloid leukemia, acute unclassified leukemia, malignant lymphoma
- Registration Number
- JPRN-UMIN000005319
- Lead Sponsor
- Osaka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with severe complications.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relapse free survival from the day of stem cell transplantation
- Secondary Outcome Measures
Name Time Method Adverse events